The Adiministrative and Mentoring Core will be responsible for all fiscal activities related to the COBRE program, including the placement of all orders and providing financial reports to the module directors and investigators. Dr. Dhanasekaran will direct the Adiministrative and Mentoring Core, which will provide all administrative functions of the COBRE program. He will be assisted by a Business Administrator and a Staff Assistant. The Business Administrator, Mr. Bobby Thomas (25%), will oversee the activities of an Administrative Assistant, Ms. Alisha Booth (100%). Mr. Thomas has been with the OUHSC for 10 years and is very convensant with the fiscal and grant management policies of OUHSC and federal funding agencies including NIH. Mr. Thomas will meet monthly with each investigator to review their accounts and mentor them in the fiscal management of sponsored research grants. Salaries for the PI, administrative staff, mentoring faculty, core directors will be paid through this core module. In addition, this core will administer the fiscal accounting for the proposed pilot projects. Coordinating meetings, travel and activities of the Internal Advisory Committee and the External Advisory Committee will be the responsibility of the Administrative Assistant, Ms. Booth, under the direction of the PI.

Public Health Relevance

Cancer represents a major health burden in the US. Ultimately, alleviating the burden of cancer will come from research: the generation of new ideas and, consequently, the development of novel agents. A COBRE grant will allow the Oklahoma Cancer Center to provide PJIs a focused mentoring experience to help them mature into independently-funded investigators contributing to the overall fight against cancer.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Exploratory Grants (P20)
Project #
5P20GM103639-02
Application #
8539813
Study Section
Special Emphasis Panel (ZRR1-RI-4)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
2
Fiscal Year
2013
Total Cost
$582,862
Indirect Cost
$188,770
Name
University of Oklahoma Health Sciences Center
Department
Type
DUNS #
878648294
City
Oklahoma City
State
OK
Country
United States
Zip Code
73117
Bastian, Anja; Matsuzaki, Satoshi; Humphries, Kenneth M et al. (2017) AG311, a small molecule inhibitor of complex I and hypoxia-induced HIF-1? stabilization. Cancer Lett 388:149-157
Pearsall, Elizabeth A; Cheng, Rui; Zhou, Kelu et al. (2017) PPAR? is essential for retinal lipid metabolism and neuronal survival. BMC Biol 15:113
Boswell-Casteel, Rebba C; Hays, Franklin A (2017) Equilibrative nucleoside transporters-A review. Nucleosides Nucleotides Nucleic Acids 36:7-30
Griffith, James; Andrade, Daniel; Mehta, Meghna et al. (2017) Silencing BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy. Oncol Rep 37:2382-2390
Banerjee Mustafi, Soumyajit; Chakraborty, Prabir Kumar; Dwivedi, Shailendra Kumar Dhar et al. (2017) BMI1, a new target of CK2?. Mol Cancer 16:56
Muralidharan, Ranganayaki; Babu, Anish; Amreddy, Narsireddy et al. (2017) Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth In Vitro and In Vivo By Disrupting the Oncogenic Activity of the RNA-binding Protein HuR. Mol Cancer Ther 16:1470-1486
Nguyen, Charles B; Houchen, Courtney W; Ali, Naushad (2017) APSA Awardee Submission: Tumor/cancer stem cell marker doublecortin-like kinase 1 in liver diseases. Exp Biol Med (Maywood) 242:242-249
Chakraborty, Prabir K; Mustafi, Soumyajit Banerjee; Xiong, Xunhao et al. (2017) MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nat Commun 8:14634
Aravindan, Sheeja; Somasundaram, Dinesh Babu; Kam, Kwok Ling et al. (2017) Retinal Degeneration Protein 3 (RD3) in normal human tissues: Novel insights. Sci Rep 7:13154
Jaiprasart, Pharavee; Yeung, Bertrand Z; Lu, Ze et al. (2017) Quantitative contributions of processes by which polyanion drugs reduce intracellular bioavailability and transfection efficiency of cationic siRNA lipoplex. J Control Release 270:101-113

Showing the most recent 10 out of 54 publications